TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36424684
Drug: High-dose indomethacin/levonorgestrel-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose indomethacin/levonorgestrel-releasing intrauterine system
Study: 36424684
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including control)
Study: 32656664
Drug: Caffeine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4 mg/Kg)
Study: 32711750
Drug: Neonatal hyperglycemia
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal hyperglycemia (blood glucose concentrations ≥153 mg/dL)
Study: 32517650
Drug: 16 hours
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 hours photoperiod with R/B/P/G light quality
Study: 32517650
Drug: R/B/P/G light
Approvals — FDA: no, EMA: no, PMDA: no
Description: R/B/P/G light quality
Study: 33271352
Drug: Palliative Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative Radiation Therapy (PRT36/12)
Study: 33271352
Drug: Concurrent Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Chemotherapy and Palliative Radiation Therapy (C-PRT40/20)
Study: 36029105
Drug: 80 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 µg vaccine
Study: 36029105
Drug: 120 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 µg vaccine
Study: 35105623
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg orally) followed by misoprostol (800 µg vaginally)
Study: 35105623
Drug: Letrozole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (10 mg orally per day for 3 days) followed by misoprostol (800 µg vaginally on the third day)
Study: 32707571
Drug: Chemical disorder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical disorder due to randomized substitution of Cd with Mg
Study: 37667213
Drug: L-PRF
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF
Study: 33154085
Drug: Angiotensin II-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin II-stimulating antihypertensives
Study: 33154085
Drug: Angiotensin II-inhibiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin II-inhibiting antihypertensives
Study: 33154085
Drug: Both antihypertensive
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both antihypertensive types
Study: 32807086
Drug: Non-statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-statin therapy (placebo)
Study: 35410935
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual provided by their GP
Study: 33358350
Drug: GTN sublingual
Normalized name: GTN Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN sublingual powder
Study: 35847464
Drug: Pharmacist-directed medication
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-directed medication reconciliation
Study: 35847464
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pharmacist-directed medication reconciliation)
Study: 34874631
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery and platinum-based chemotherapy
Study: 34298113
Drug: 3D-printed oblong
Normalized name: CYDONIA OBLONGA LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D-printed oblong tablets
Study: 34298113
Drug: 3D-printed round
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D-printed round tablets
Study: 32089783
Drug: Health resort
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health resort treatment
Study: 33793743
Drug: OABP+ (Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OABP+ (Oral Antibiotic Prophylaxis with Mechanical Bowel Preparation)
Study: 33793743
Drug: OABP- (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: OABP- (No Oral Antibiotic Prophylaxis with Mechanical Bowel Preparation)
Study: 34949502
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TA) drops
Study: 32037862
Drug: Pressure garment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure garment application (long glove) for 6 hours/day in addition to 2 hours/week conventional occupational therapy
Study: 32037862
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy for 2 hours/week
Study: 36194950
Drug: Cabazitaxel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (25 mg/m2, 6 cycles, three-weekly)
Study: 36194950
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2, weekly)
Study: 35551978
Drug: Qirui Weishu
Normalized name: BENZODODECINIUM BROMIDE 2 g in 500 mL EXTRACORPOREAL LIQUID [Youjie Weishi Antibacterial Hand Wash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qirui Weishu capsule
Study: 35551978
Drug: Sanjiu Weitai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanjiu Weitai capsule
Study: 34380299
Drug: Local magneto-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local magneto-therapy
Study: 34380299
Drug: General magneto-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: General magneto-therapy
Study: 35652491
Drug: Restrictive IV
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive IV fluid administration (24 hours)
Study: 35652491
Drug: Restrictive IV
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive IV fluid administration
Study: 35652491
Drug: Restrictive IV
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive IV fluid administration and Standard care
Study: 36066862
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management plus combined behavioral intervention (MMCBI)
Study: 35494290
Drug: Theracurmin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theracurmin at 180 mg per day
Study: 33433317
Drug: tofacitinib citrate
Normalized name: Tofacitinib Citrate
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tofacitinib citrate test formulation (T)
Study: 33433317
Drug: tofacitinib citrate
Normalized name: Tofacitinib Citrate
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tofacitinib citrate reference formulation (R)
Study: 34465695
Drug: Linaclotide 290
Normalized name: LINACLOTIDE 290MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide 290 μg daily for 12 weeks
Study: 37644897
Drug: THC 10
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 10 mg
Study: 32911214
Drug: Control (laboratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (laboratory tests and free ART medication)
Study: 33089368
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (transcutaneous electrical nerve stimulation, hot pack, ultrasound treatments, Codman's and range of motion exercises)
Study: 33089368
Drug: Balneotherapy added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balneotherapy added to physical therapy
Study: 32484432
Drug: Carer administration
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carer administration of as-needed subcutaneous medication (intervention group)
Study: 32250061
Drug: Subcrestal implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal implant placement
Study: 36175107
Drug: Deliberate practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deliberate practice training using role-play and Skillsetter, an online skill-building system with therapy videos, for 15 hours of classroom participation and homework.
Study: 34280455
Drug: Palonosetron (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.075 mg)
Study: 35034532
Drug: Optimised regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised regimen (7 × 2 L 2.27% glucose + 5 × 2 L 0.1% glucose over 8 h)
Study: 35034532
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (6 × 2 L 1.36% glucose over 9 h)
Study: 32542644
Drug: Quadrivalent HPV-vaccine
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV-vaccine
Study: 36104302
Drug: Vibegron 75
Normalized name: vibegron 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibegron 75 mg as an intact tablet
Study: 36104302
Drug: Vibegron 75
Normalized name: vibegron 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibegron 75 mg crushed and mixed with applesauce
Study: 36104302
Drug: Vibegron 75
Normalized name: vibegron 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibegron 75 mg (both intact and crushed)
Study: 32482616
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after one-month dual antiplatelet therapy (DAPT)
Study: 33963943
Drug: 0.05% EGCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% EGCG solution + RelyX U200
Study: 33327746
Drug: Lower HDL
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower HDL cholesterol (1 mmol/L or 39 mg/dL)
Study: 33327746
Drug: Genetically determined
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically determined lower HDL cholesterol (1 mmol/L or 39 mg/dL)
Study: 34791007
Drug: Camelina oil
Normalized name: Camelina sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camelina oil (1.5 g ALA/d)
Study: 32706428
Drug: Testosterone Replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Replacement Therapy (TRT) for 6 months
Study: 37965466
Drug: Proton beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton beam therapy (PBT)
Study: 34699271
Drug: Transoral surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transoral surgery (TOS) plus 50 Gy postoperative radiation therapy (RT)
Study: 34699271
Drug: Transoral surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transoral surgery (TOS) plus 60 Gy postoperative radiation therapy (RT)
Study: 34699271
Drug: Transoral surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transoral surgery (TOS) plus 66 Gy RT and weekly cisplatin
Study: 34699271
Drug: Functional assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional assessment of cancer therapy-head and neck
Study: 33590471
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) monotherapy
Study: 36729441
Drug: LipiFlow treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipiFlow treatment
Study: 34349267
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin therapy (using faster insulin aspart)
Study: 34349267
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin therapy (control)
Study: 34349267
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin therapy
Study: 34508882
Drug: Calcitriol 0.5
Normalized name: CALCITRIOL 0.5MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.5 μg daily for 14 days
Study: 34930165
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy
Study: 33838357
Drug: Desmopressin (DDAVP)
Normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (DDAVP) at a maximum dose of 0.2 micrograms per kg
Study: 34971304
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (3 mL)
Study: 33438009
Drug: Low added
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low added sugar intake (0 g/d)
Study: 33438009
Drug: Medium added
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium added sugar intake (75 g/d)
Study: 33438009
Drug: High added
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High added sugar intake (150 g/d)
Study: 32360142
Drug: Aminosidine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminosidine (15 mg/kg, subcutaneously, once daily, for 28 days) and allopurinol (10 mg/kg, per os, twice daily, for 6 months)
Study: 32360142
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate (100 mg/kg SC, once daily, for 28 days) and allopurinol (10 mg/kg, per os, twice daily, for 6 months)
Study: 32360142
Drug: Meglumine antimoniate-allopurinol
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate-allopurinol combination
Study: 32360142
Drug: Aminosidine-allopurinol combination
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine-allopurinol combination
Study: 35242798
Drug: Control formulation
Normalized name: nut.tx, weight loss-control formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formulation
Study: 33885035
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (n=75)
Study: 33885035
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (n=77)
Study: 35147086
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Liriope platyphylla extract
Study: 33946101
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages sent via WhatsApp during the study period (group 1)
Study: 37716952
Drug: atrasentan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: atrasentan 0.75 mg/day
Study: 36054166
Drug: Topical methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical methotrexate 1% gel (MTX)
Study: 36054166
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol 0.005% cream (CPL)
Study: 32938723
Drug: Radical surgery
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical surgery including pelvic and para-aortic lymphadenectomy and subsequent platinum-based chemotherapy
Study: 32817407
Drug: PIB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIB with saline infusion (group 1, n=23)
Study: 33064413
Drug: N +
Normalized name: Lutein + Kale
Approvals — FDA: no, EMA: no, PMDA: no
Description: N + C supplementation (520 mg nitrate and 6 g citrulline)
Study: 616191460
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) given prophylactically at 20-50% of daily dose
Study: 33235439
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebivolol plus 20 mg rosuvastatin (NEBI/RSV)
Study: 33235439
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebivolol (NEBI)
Study: 33235439
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rosuvastatin (RSV)
Study: 32539663
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg weight-based dosing (to a maximum of 200 mg)
Study: 32539663
Drug: Flat dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat dosing of 200 mg
Study: 32539663
Drug: Vial sharing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vial sharing using 100 mg vials
Study: 34697965
Drug: d-amphetamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (30 mg BID) during week 1, switched to placebo during weeks 2-3, placebo during week 4
Study: 36309966
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose amitriptyline (10–20 mg based on self‐titration)
Study: 32282044
Drug: Telehealth intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telehealth intervention (ENABLE CHF-PC) consisting of four weekly psychosocial and problem-solving support telephonic sessions lasting 20-60 minutes facilitated by a trained nurse coach plus monthly follow-up for 48 weeks.
Study: 34979571
Drug: Monthly video
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly video consultations plus regular care (IG)
Study: 34747448
Drug: Ansofaxine 40
Normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ansofaxine 40 mg/d
Study: 34747448
Drug: Ansofaxine 80
Normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ansofaxine 80 mg/d
Study: 34747448
Drug: Ansofaxine 120
Normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ansofaxine 120 mg/d
Study: 34747448
Drug: Ansofaxine 160
Normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ansofaxine 160 mg/d
Study: 35372992
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV iron administered proactively
Study: 35372992
Drug: Low-dose IV
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IV iron administered reactively
Study: 32021087
Drug: 3 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ng/kg/min AM via continuous 12-h intravenous infusion
Study: 32021087
Drug: 9 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 ng/kg/min AM via continuous 12-h intravenous infusion
Study: 32021087
Drug: 15 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ng/kg/min AM via continuous 12-h intravenous infusion
Study: 34617277
Drug: Ketoprofen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (3 mg/kg, Ketofen 10%, Ceva Animal Health)
Study: 34617277
Drug: Control (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (topical application of oxytetracycline spray only)
Study: 33724373
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (tenofovir disoproxil fumarate/emtricitabine with a third agent)
Study: 38609322
Drug: tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 5 mg two times per day
Study: 38609322
Drug: tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 10 mg two times per day
Study: 33249580
Drug: Galcanezumab (GMB)
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab (GMB) 120 mg
Study: 35508860
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) intervention at bilateral Zusanli (ST 36), Shangjuxu (ST 37), Xiajuxu (ST 39), Tianshu (ST 25), and Zhongwan (RN 12) acupoints, 30 min per time, twice daily, for 7 days
Study: 33455137
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment group (monosialotetrahexose ganglioside sodium + conventional rehabilitation)
Study: 33455137
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (conventional rehabilitation)
Study: 33020204
Drug: Cetuximab (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (initial dose of 400 mg/m2 IV followed by weekly doses of 250 mg/m2, one cycle = 4 weeks)
Study: 34571095
Drug: Lesogaberan (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan (120 mg MR)
Study: 33287865
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment (MBT) for 12 months
Study: 33789243
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 5 mg·kg‐1 body mass
Study: 32781992
Drug: Oral ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ranitidine (3 mg/kg/day) for 10 days
Study: 32781992
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 mg of oral vitamin C tablet) for 10 days
Study: 35859277
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (SBP ≤ 130 mmHg)
Study: 35859277
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SBP ≤ 140 mmHg)
Study: 34646359
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (n = 33)
Study: 39112795
Drug: Study treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment
Study: 34042953
Drug: Biological VNN
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological VNN (BioVNN)
Study: 34159208
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PRP treatment)
Study: 32801102
Drug: Adjunctive eslicarbazepine
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive eslicarbazepine acetate (ESL) 1200 mg once daily (QD)